Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and symptoms of arthritis, including osteoarthritis and rheumatoid arthritis. It works by inhibiting cyclooxygenase (COX) enzymes, particularly showing preferential selectivity for COX-2 over COX-1, which leads to reduced synthesis of prostaglandins involved in inflammation, pain, and fever. Etodolac has analgesic and antipyretic properties but does not cure underlying disease; it only manages symptoms as long as therapy continues. The drug was patented in 1971 and approved for medical use in 1985. Developed by Wyeth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etodolac.